A case of myopericarditis following administration of the Pfizer COVID-19 vaccine

Zoey Morton, Danetta Green, Matt Grisham


Numerous vaccines have been developed to address the COVID-19 pandemic, the most frequently administered are the Moderna and Pfizer-BioNTech (Pfizer) mRNA COVID-19 vaccines. Of 177 million individuals that have full vaccination status, there have been 1,148 cases of myocarditis or pericarditis reported. At this time, the relationship between myopericarditis and the Pfizer mRNA COVID-19 vaccine has not been well established in current literature due to the novelty of the vaccine. We discuss a 16-year-old male who presented to the emergency department with chest pain 48 hours after receiving his second dose of the Pfizer COVID-19 vaccine. His laboratory and electrocardiogram findings were consistent with acute myopericarditis and work-up did not reveal an obvious etiology. After starting anti-inflammatory therapies, the patient’s symptoms and laboratory markers improved and the patient was discharged from the hospital expected to make a full recovery. This case demonstrates the rapid recovery with no sequelae following this adverse effect, highlighting that the benefits of the COVID-19 vaccination most likely outweigh the risks.



COVID-19 vaccine; myopericarditis; pediatric; adverse effect

Full Text:



Centers for Disease Control and Prevention. COVID Data Tracker Weekly Review. [https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html available at 01.11.2022]

Centers for Disease Control and Prevention. Understanding How COVID-19 Vaccines Work. [https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/how-they-work.html available at 01.11.2022]

Centers for Disease Control and Prevention. Selected Adverse Events Reported after COVID-19 Vaccination. [https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html available at 01.11.2022]

Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: Update from the Advisory Committee on Immunization Practices—United States. MMWR Morb Mortal Wkly Rep. 2021; 70(27):977-982. http://dx.doi.org/10.15585/mmwr.mm7027e2

Salah HM, Mehta JL. COVID-19 vaccine and myocarditis. Am J Cardiol. 2021; 157:146-148. https://doi.org/10.1016/j.amjcard.2021.07.009

Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation. 2021; 144(6):471-484. https://doi.org/10.1161/CIRCULATIONAHA.121.056135

Vojdani A, Kharrazian D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin Immunol. 2020; 217:108480. https://doi.org/10.1016/j.clim.2020.108480

U.S. Department of Health and Human Services. Vaccine Adverse Event Reporting System. [https://vaers.hhs.gov/ available at 01.11.2022]

DOI: http://dx.doi.org/10.22551/2022.34.0901.10195

Copyright (c) 2022 Zoey Morton, Danetta Green, Matt Grisham

Creative Commons License
Archive of Clinical Cases is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


ISSN: 2360-6975